Ligand Pharmaceuticals Overview
- Year Founded
-
1987
- Status
-
Public
- Employees
-
68
- Stock Symbol
-
LGND
- Investments
-
32
- Share Price
-
$109.41
- (As of Thursday Closing)
Ligand Pharmaceuticals General Information
Description
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Contact Information
Website
www.ligand.comCorporate Office
- 555 Heritage Drive
- Suite 200
- Jupiter, FL 33458
- United States
Corporate Office
- 555 Heritage Drive
- Suite 200
- Jupiter, FL 33458
- United States
Ligand Pharmaceuticals Stock Performance
As of 20-Mar-2025, Ligand Pharmaceuticals’s stock price is $109.41. Its current market cap is $2.11B with 19.3M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $109.41 | $108.03 | $67.72 - $129.90 | $2.11B | 19.3M | 112K | -$0.22 |
Ligand Pharmaceuticals Financials Summary
As of 31-Dec-2024, Ligand Pharmaceuticals has a trailing 12-month revenue of $167M.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 1,812,353 | 1,812,353 | 1,061,103 | 1,120,970 |
| Revenue | 167,133 | 167,133 | 131,314 | 196,245 |
| EBITDA | 32,739 | 32,739 | 93,126 | 87,298 |
| Net Income | (4,032) | (4,032) | 52,154 | (33,361) |
| Total Assets | 941,774 | 941,774 | 787,216 | 762,668 |
| Total Debt | 7,105 | 7,105 | 6,165 | 87,746 |
Ligand Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Ligand Pharmaceuticals Comparisons
Industry
Financing
Details
Ligand Pharmaceuticals Competitors (23)
One of Ligand Pharmaceuticals’s 23 competitors is Alkermes, a Formerly VC-backed company based in Dublin, Ireland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Alkermes | Formerly VC-backed | Dublin, Ireland | ||||
| Enzon Pharmaceuticals | Corporation | Cranford, NJ | ||||
| Ironwood Pharmaceuticals | Formerly VC-backed | Boston, MA | ||||
| Durect | Formerly VC-backed | Cupertino, CA | ||||
| Aclaris Therapeutics | Formerly VC-backed | Wayne, PA |
Ligand Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Ligand Pharmaceuticals Patents
Ligand Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240294565-A1 | Unnatural configuration nucleotide prodrug compounds | Pending | 17-May-2021 | ||
| US-20230391807-A1 | Antiviral prodrug compounds | Pending | 21-Oct-2020 | ||
| EP-4232456-A1 | Antiviral prodrug compounds | Pending | 21-Oct-2020 | ||
| US-11566041-B2 | Nucleotide prodrug compounds | Active | 21-Apr-2020 | ||
| EP-4143199-A1 | Nucleotide prodrug compounds | Pending | 21-Apr-2020 | C07F9/657127 |
Ligand Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Ligand Pharmaceuticals Investments & Acquisitions (32)
Ligand Pharmaceuticals’s most recent deal was a PIPE with Palvella Therapeutics for . The deal was made on 12-Dec-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Palvella Therapeutics | 12-Dec-2024 | PIPE | Drug Discovery | ||
| InvIOs (Biotechnology) | 15-Oct-2024 | Early Stage VC | Biotechnology | ||
| APEIRON Biologics | 15-Jul-2024 | Merger/Acquisition | Pharmaceuticals | ||
| MacroGenics (Anti-CD3 Monoclonal Antibody Teplizumab) | 01-Nov-2023 | Corporate Asset Purchase | Buildings and Property | ||
| NVN Liquidation | 27-Sep-2023 | Merger/Acquisition | Pharmaceuticals |
Ligand Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated January, 23, 2024
24.46 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,946
Rank
Percentile
Pharmaceuticals
Industry
of 847
Rank
Percentile
Biotechnology
Subindustry
of 366
Rank
Percentile
Ligand Pharmaceuticals Exits (11)
Ligand Pharmaceuticals’s most recent exit was on 12-Dec-2024 from Palvella Therapeutics. The exit was categorized as with 14 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Palvella Therapeutics | 12-Dec-2024 | Completed |
|
||
| Pelican Expression | 01-Oct-2020 | Completed |
|
||
| Palvella Therapeutics | 28-May-2020 | Completed |
|
||
| Dianomi Therapeutics | 04-Feb-2019 | Completed |
|
||
| Palvella Therapeutics | 18-Dec-2018 | Corporate | Completed |
Ligand Pharmaceuticals Affiliates
Subsidiaries (3)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| NVN Liquidation | Durham, NC | 2006 | |
| APEIRON Biologics | Vienna, Austria | 2003 | |
| CyDex Pharmaceuticals | San Diego, CA | 1993 |
Ligand Pharmaceuticals FAQs
-
When was Ligand Pharmaceuticals founded?
Ligand Pharmaceuticals was founded in 1987.
-
Where is Ligand Pharmaceuticals headquartered?
Ligand Pharmaceuticals is headquartered in Jupiter, FL.
-
What is the size of Ligand Pharmaceuticals?
Ligand Pharmaceuticals has 68 total employees.
-
What industry is Ligand Pharmaceuticals in?
Ligand Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Ligand Pharmaceuticals a private or public company?
Ligand Pharmaceuticals is a Public company.
-
What is Ligand Pharmaceuticals’s stock symbol?
The ticker symbol for Ligand Pharmaceuticals is LGND.
-
What is the current stock price of Ligand Pharmaceuticals?
As of 20-Mar-2025 the stock price of Ligand Pharmaceuticals is $109.41.
-
What is the current market cap of Ligand Pharmaceuticals?
The current market capitalization of Ligand Pharmaceuticals is $2.11B.
-
What is Ligand Pharmaceuticals’s current revenue?
The trailing twelve month revenue for Ligand Pharmaceuticals is $167M.
-
Who are Ligand Pharmaceuticals’s competitors?
Alkermes, Enzon Pharmaceuticals, Ironwood Pharmaceuticals, Durect, and Aclaris Therapeutics are some of the 23 competitors of Ligand Pharmaceuticals.
-
What is Ligand Pharmaceuticals’s annual earnings per share (EPS)?
Ligand Pharmaceuticals’s EPS for 12 months was -$0.22.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
